News and Announcements
RISKflo Announced a 5-year Contract with a Major Financial Services Company
- Published May 19, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
RISKflo, a multi-stakeholder collaborative review, approval, monitoring, and reporting platform announced a renewal of a major International Bank contract – of 5 years (3+1+1). The bank confirmed its commitment to RISKflo as a best-in-class provider of third-party risk management (TPRM) solutions to the financial services industry.
The latest renewal will give RISKflo over 10 years of connection to this major financial service group. It has enabled RISKflo additional development and deployment of a world-leading platform which is a “no-code” highly flexible business solution. The major client intends to extend the usage of the RISKflo platform and apply SmartScripts™ to different business entities beyond banking, including but not limited to their insurance businesses. In support of this direction, RISKflo has moved to a user-pays pricing model and removed all previous contract-based technical and commercial constraints. This essentially extends to the client the unfettered ability to create ‘Super’ SmartScripts™ for any use case and will be managed by the client by their internal team.
Regulatory Compliance is one of the biggest issues facing Financial Institutions today. With over 200 regulators, financial institutions are faced with new regulations, on average, every 3 minutes.
Unfortunately, existing automation solutions are not built to facilitate the deployment of this sort of change to regulations and policy in a large complex financial institution. By comparison, RISKflo provides third-party risk and compliance solutions across 19 countries in the Asia Pacific. The RISKflo solution recently allowed the bank to complete remediation of third parties required by the regulator to be completed in 2-3 days compared to 3-6 months previously.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
